نتایج جستجو برای: lymphocyte associated antigen 4 ctla

تعداد نتایج: 2795929  

Journal: :Asian Pacific journal of cancer prevention : APJCP 2014
Sachin Minhas Sunita Bhalla Yogender Shokeen Mayank Jauhri Renu Saxena Ishwar Chandra Verma Shyam Aggarwal

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is an important protein involved in the regulation of the immune system. The +49 G/A polymorphism is the only genetic variation in the CTLA-4 gene that causes an amino acid change in the resulting protein. It is therefore the most extensively studied polymorphism among all CTLA-4 genetic variants and contributions to increasing the likelihood of develop...

2015
Frederick J Kohlhapp Joseph R Broucek Tasha Hughes Erica J Huelsmann Jevgenijs Lusciks Janet P Zayas Hubert Dolubizno Vidyaratna A Fleetwood Alisa Grin Graham E Hill Joseph L Poshepny Arman Nabatiyan Carl E Ruby Joshua D Snook Jai S Rudra Jason M Schenkel David Masopust Andrew Zloza Howard L Kaufman

BACKGROUND Melanoma is one of the few types of cancer with an increasing annual incidence. While a number of immunotherapies for melanoma have been associated with significant clinical benefit, including high-dose IL-2 and cytotoxic T lymphocyte antigen 4 (CTLA-4) blockade, clinical response to either of these single agents has been limited to 11-20% of treated patients. Therefore, in this stud...

2016
Elizabeth I. Buchbinder Anupam Desai

The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) immune checkpoints are negative regulators of T-cell immune function. Inhibition of these targets, resulting in increased activation of the immune system, has led to new immunotherapies for melanoma, non-small cell lung cancer, and other cancers. Ipilimumab, an inhibitor of CTLA-4, is approved for the treatme...

2005
Jingjing Sun Padmanee Sharma

The cytotoxic T lymphocyte antigen-4 (CTLA-4) molecule on T cells acts to maintain homeostasis by regulating the proliferation of recently activated T cells. Blockade of CTLA-4 by anti-CTLA-4 antibody enhances T cell responses and has elicited significant tumor regression in some cancer patients. Clinical trials are ongoing to investigate the efficacy of anti-CTLA-4 antibody as a cancer therape...

Journal: :Molecular medicine reports 2014
Man Chen Ying Chang Feng Tang Qiong-Hui Xie Jin Li Hong Yang Xing-Xing He Ju-Sheng Lin

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates T-cell activation and Th1/Th2 cytokine production and is involved in the immune response against Hepatitis B virus (HBV) infection. To detect the association of the CTLA-4 gene polymorphisms with susceptibility to HBV infection a hospital-based case-control study was conducted. A total of 1,119 unrelated individuals were recruited. ...

Journal: :Immunological reviews 2009
Christopher E Rudd Alison Taylor Helga Schneider

SUMMARY T-cell activation is mediated by antigen-specific signals from the TCRzeta/CD3 and CD4-CD8-p56lck complexes in combination with additional co-signals provided by coreceptors such as CD28, inducible costimulator (ICOS), cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death (PD-1), and others. CD28 and ICOS provide positive signals that promote and sustain T-cell responses, while CT...

2017
Heiko Sic Matthaios Speletas Vanessa Cornacchione Maximillian Seidl Martin Beibel Bolan Linghu Fan Yang Eirini Sevdali Anastasios E. Germenis Edward J. Oakeley Eric Vangrevelinghe Andreas W. Sailer Elisabetta Traggiai Hermann Gram Hermann Eibel

Heterozygous mutations in the cytotoxic T lymphocyte antigen-4 (CTLA-4) are associated with lymphadenopathy, autoimmunity, immune dysregulation, and hypogammaglobulinemia in about 70% of the carriers. So far, the incomplete penetrance of CTLA-4 haploinsufficiency has been attributed to unknown genetic modifiers, epigenetic changes, or environmental effects. We sought to identify potential genet...

2014
Kibem Kim Andrew Skora Zhaobo Li Ada Tam Luis Diaz Nickolas Papadopolous Lee Blosser Kenneth Kinzler Bert Vogelstein Shibin Zhou

Impressive responses have been observed in patients treated with checkpoint inhibitory anti-programmed cell death-1 (PD-1) or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies. However, immunotherapy against poorly immunogenic cancers remains a challenge. Here we report that treatment with both anti-PD-1 and anti-CTLA-4 antibodies was unable to eradicate large, modestly immun...

Journal: :Journal of Community Hospital Internal Medicine Perspectives 2023

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that widely used for the management of many solid-organ and hematologic cancers. These agents work by inhibition cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), PD ligand 1 (PD-L1). Hyperactivation immune system results in ICI-associated adverse events. Simultaneous hepatotoxicity colitis associa...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید